AdvaMed® Advancements: Q3 2026 Report
Explore AdvaMed’s Q3 2026 Report to see how advocacy, member engagement, and policy progress are advancing innovation, expanding patient access to medtech, and strengthening the industry to serve patients.
AdvaMed Advancements
AdvaMed Concludes Record-Breaking MedTech Conference 2026
BOSTON—AdvaMed, the Medtech Association, concluded The MedTech Conference 2026, convening more than 4,470 attendees from 2,050 companies from 40 countries for the global medtech industry’s premier annual gathering.
Supporting an Effective, Timely FDA Medtech Review Process
The Medical Device User Fee Amendments (MDUFA) program ensures the FDA has the proper resources to fulfill the timely medtech review patients and innovators need.
Supporting Small Medtech Innovators (SBIR)
AdvaMed supports the competitive federal grant programs integral to next-generation medtech solutions for patients.
Medtech Showcase & Reception on Capitol Hill
Experience the future of health care at the 2026 Medtech Showcase and Reception on Capitol Hill. Join AdvaMed® on September 16 for an interactive event featuring more than 25 medtech…
AdvaMed® Advancements: Q2 2026 Report
Explore AdvaMed’s Q2 2026 Report to see how advocacy, member engagement, and policy progress are advancing innovation and strengthening the medtech industry.
AdvaMed Earns WTOP News Regional Top Workplaces 2026 Award, Culture Excellence Awards
Washington, D.C.—AdvaMed, the largest trade association representing medtech innovators, announced today it is a WTOP News Top Workplaces 2026 award winner in the Washington, D.C., region and received five Culture…
AdvaMed® Advancements: Q1 2026 Report
Explore AdvaMed®’s Q1 2026 report on medtech policy, regulatory trends, reimbursement, and advocacy driving innovation and patient access.
2025 Annual Report
Explore AdvaMed®’s key achievements and milestones in 2025 on behalf of our member companies and the patients they serve.
AdvaMed® Plays Tariff Chess, Trump Plays Checkers
As tariff uncertainty continues in 2025,AdvaMed® plays tariff chess, advocating for predictable, zero-for-zero policies to protect medtech innovation and access.